Table 2: Atypical fractures observed during

the follow-up period of the cohort from 2008 to 2024.

Most fractures ocurred

in patients under continuos treatment.

Type

of OI

Age

Gender

Number

of doses

Location

Type of

treatment

I

15

F

10

Femur

Continuous

I

11

M

6

Femur

Continuous

I

12

F

10

Bilateral

femur

Continuous

IV

6

F

3

Femur

Continuous

III

15

M

15

Femur

Continuous

III

3

F

3

Femur

Intermittent

III

15

M

4

Femur

Continuous

IV

8

M

14

Humerus

Continuous

IV

18

F

9/13

Femur/ulna

Continuous

III

10

M

10

Femur

Continuous

I

12

M

14

Femur

Continuous

III

9

M

4

Femur

Continuous

I

15

M

12

Radius

Intermittent

I

15

M

9

Femur

Continuous

III

8

M

6

Femur

Intermittent

III

14

M

3

Femur

Intermittent

III

12

M

6/12

Right femur

/ left femur

Continuous

IV

14

F

7

Femur

Intermittent

I

14

M

6

Femur

Continuous

IV

10

M

3

Femur

Continuous

I

11

F

10

Femur

Continuous

OI = osteogenesis imperfecta.

F = female.

M = male.

C = continuous treatment.

I = intermittent treatment.